Amal Therapeutics
Geneva
About Amal Therapeutics
Amal Therapeutics SA is a privately held Swiss/German biotech start-up company and spin-off from the University of Geneva. Amal Therapeutics was incorporated in September 2012. Amal uses its proprietary cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $45.3M
- Funding stage: M&A
- Last round: Series B (Nov 2018)
- Website: amaltherapeutics.com
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology, Life Science, Neuroscience, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/amal-therapeutics-70388 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.